Advertisement


Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study

2024 ASCO Annual Meeting

Advertisement

Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
ECHELON-3 was a Phase 3 double-blind placebo-controlled trial in patients with diffuse large B-cell lymphoma that had relapsed or refractory disease to prior therapy. In this study, they particularly enrolled those patients that were either ineligible for or had received prior treatment with both CAR-T cell therapy or hematopoietic stem cell transplant. In this trial, investigators evaluated a combination of lenalidomide and rituximab with either brentuximab vedotin or placebo. It was a median of three prior therapies, and in general the patients were heavily pre-treated, including approximately half of patients having primary refractory disease, 30% of patients with prior CAR-T cell exposure, and approximately 15% of patients had prior bispecific antibody exposure. We see with the combination of brentuximab vedotin, lenalidomide and rituximab, that this is a very active regimen, and we're seeing high complete response rates along with encouraging durability at this point. These improved responses were encouragingly seen in both CD30-positive and CD30-negative patients, and this translated into an improvement in progression-free along with overall survival. And importantly, we saw some improvements in really key subsets of patients with high-risk features such as those with high IPI, those patients with prior CAR-T exposure, along with those patients with nongerminal center cell of origin, and this regimen though was not without its own toxicity, and we saw higher incidence of Grade 3 or greater adverse events in the [inaudible 00:01:40] and rituximab arm compared to lenalidomide-rituximab alone, particularly those manifested as hematologic toxicity, along with increased risk of peripheral neuropathy. In general this was an active regimen, and is particularly encouraging for those patients that may not be either eligible for, or have previously received, therapy with things like bispecific antibodies, CAR-T or hematopoietic stem cell transplant. This is currently an interim analysis, and we will need longer follow-up in order to have a better understanding of long-term outcomes, particularly in terms of both safety and efficacy.

Related Videos

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Lymphoma

Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide

Joshua D. Brody, MD, of the Icahn School of Medicine at Mount Sinai, discusses results from the EPCORE NHL-2 study, which was designed to evaluate the safety and efficacy of epcoritamab-bysp plus rituximab and lenalidomide in the first-line setting for patients with follicular lymphoma and to assess epcoritamab as maintenance therapy in this population (Abstract 7014).

Skin Cancer

Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab

Pauline Funchain, MD, of Stanford University, and Caroline Robert, MD, PhD, of Gustave Roussy, discuss phase II findings showing that combining encorafenib and binimetinib followed by ipilimumab and nivolumab vs ipilimumab and nivolumab can improve progression-free survival in patients with BRAF-V600E/K-mutated melanoma characterized by high lactate dehydrogenase and liver metastases (Abstract LBA9503).

Leukemia

Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors

Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center, discusses a network meta-analysis showing that zanubrutinib appears to be the most efficacious Bruton’s tyrosine kinase (BTK) inhibitor for patients with high-risk relapsed or refractory chronic lymphocytic leukemia. It offers delayed disease progression and favorable survival and response, compared with alternative BTK inhibitors (Abstract 7048).

 

Breast Cancer

Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use

Emily L. Podany, MD, of Washington University, St. Louis, discusses disparities in the use of PI3K inhibitors for Black patients with estrogen receptor–positive, HER2-negative metastatic breast cancer while other drugs that do not require genomic profiling were similarly used (Abstract 1017). 

Advertisement

Advertisement




Advertisement